Bicara Therapeutics
Jeltje Schulten currently serves as Senior Vice President of Clinical and Medical Affairs at Bicara Therapeutics, starting in March 2024. Prior to this role, Jeltje held various positions at Merck Healthcare KGaA from January 2013 to March 2024, including Global Executive Medical Director for Early Development Oncology and Immuno-Oncology, where leadership involved facilitating innovative compound development through collaborations with academia. Other roles at Merck included TA Lead for Head and Neck Cancer, Senior Director of Medical Affairs, and Global Medical Affairs Director for Erbitux. Previous experience at Merck Serono and Merck KGaA focused on market access, marketing, and commercialization for oncology, highlighted by successful product launches and key opinion leader engagement. Jeltje earned dual MBA degrees in Health Care and Health Finance & Economics from Case Western Reserve University in 1997.
This person is not in any teams
This person is not in any offices
Bicara Therapeutics
Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of immunotherapy. The company's dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy.